Plasmodium falciparum gametocyte dynamics after pyronaridine-artesunate or artemether-lumefantrine treatment

Malar J. 2018 Jun 4;17(1):223. doi: 10.1186/s12936-018-2373-7.

Abstract

Background: Artemisinin-based combinations differ in their impact on gametocyte prevalence and density. This study assessed female and male gametocyte dynamics after treating children with uncomplicated Plasmodium falciparum malaria with either pyronaridine-artesunate (PA) or artemether-lumefantrine (AL).

Methods: Kenyan children with uncomplicated Plasmodium falciparum malaria were included and randomly assigned to PA or AL treatment. Filter paper blood samples were collected as a source of RNA for quantitative reverse-transcription PCR (qRT-PCR) and nucleic acid sequence based amplification (QT-NASBA) to detect female gametocytes (targeting Pfs25 mRNA). Male gametocytes were detected by qRT-PCR (targeting PfMGET mRNA). Duration of gametocyte carriage, the female and male gametocyte response and the agreement between qRT-PCR and QT-NASBA were determined.

Results: The mean duration of female gametocyte carriage was significantly longer for PA (4.9 days) than for AL (3.8 days) as estimated by QT-NASBA (P = 0.036), but this difference was less clear when determined by Pfs25 qRT-PCR (4.5 days for PA and 3.7 for AL, P = 0.166). qRT-PCR based female gametocyte prevalence decreased from 100% (75/75) at baseline to 6.06% (4/66) at day 14 in the AL group and from 97.7% (83/85) to 13.9% (11/79) in the PA group. Male gametocyte prevalence decreased from 41.3% (31/75) at baseline to 19.7% (13/66) at day 14 in the AL group and from 35.3% (30/85) to 22.8% (18/79) in the PA group. There was good agreement between Pfs25 qRT-PCR and QT-NASBA female gametocyte prevalence (0.85, 95% CI 0.82-0.87).

Conclusions: This study indicates that female gametocyte clearance may be slightly faster after AL compared to PA. Male gametocytes showed similar post-treatment clearance between study arms. Future studies should further address potential differences between the post-treatment transmission potential after PA compared to AL. Trial registration This study is registered at clinicaltrials.gov under NCT02411994. Registration date: 8 April 2015. https://clinicaltrials.gov/ct2/show/NCT02411994?term=pyronaridine-artesunate&cond=Malaria&cntry=KE&rank=1.

Keywords: Artemether–lumefantrine; Gametocytes; Plasmodium falciparum; Pyronaridine–artesunate.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Antimalarials / therapeutic use*
  • Artemether, Lumefantrine Drug Combination / therapeutic use*
  • Artesunate / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Kenya
  • Malaria, Falciparum / drug therapy*
  • Male
  • Naphthyridines / therapeutic use*
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / isolation & purification
  • Reverse Transcriptase Polymerase Chain Reaction
  • Self-Sustained Sequence Replication

Substances

  • Antimalarials
  • Artemether, Lumefantrine Drug Combination
  • Naphthyridines
  • Artesunate
  • pyronaridine

Associated data

  • ClinicalTrials.gov/NCT02411994